Risk Factors for Poor Cutaneous Cell Cancer Outcomes Identified

This article originally appeared here.
Share this content:
Risk Factors ID'd for Poor Cutaneous Cell CA Outcomes
Risk Factors ID'd for Poor Cutaneous Cell CA Outcomes

(HealthDay News) -- The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond fat, poor differentiation, and location, according to a study published in the May issue of JAMA Dermatology.

To identify risk factors associated with poor outcomes in primary CSCC, Chrysalyne D. Schmults, M.D., from Brigham and Women's Hospital in Boston, and colleagues retrospectively analyzed CSCC outcomes for 985 patients with 1,832 tumors.

The researchers found that over a median follow-up of 50 months, local recurrence occurred in 4.6% of patients, 3.7% developed nodal metastases, and 2.1% died of CSCC. Independent predictors for nodal metastasis and disease-specific death included a tumor diameter of at least 2 cm (subhazard ratios, 7.0 and 15.9, respectively), poor differentiation (6.1 and 6.7), invasion beyond fat (9.3 and 13.0), and ear or temple location (3.8 and 5.9), according to multivariate competing risk analyses. Disease-specific death was associated with perineural invasion (subhazard ratio, 3.6) and anogenital location, but few cases were anogenital. Poor differentiation (subhazard ratio, 1.3) and invasion beyond fat (1.7) correlated with overall death.

"Cutaneous squamous cell carcinoma carries a low but significant risk of metastasis and death," write the authors. "Accurate risk estimation of outcomes from population-based data and clinical trials proving the utility of disease-staging modalities and adjuvant therapy is needed."

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs